CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for SCL Science Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

SCL Science Inc
1206-1210, Ace Hitech City 2 Cha,
25, Seonyu-ro 13-gil, Yeongdeungpo-gu
Phone: +82 269591338p:+82 269591338 SEOUL, 07282  South Korea Ticker: 246960246960
Business Summary
SCL Science Inc, formerly InnoTherapy Inc, is a Korea-based company principally engaged in the research, development, manufacture, export and sale of medical hemostatic agents. The main developed products include medical hemostats and sealants with biomimetic technology. In addition, the Company is engaged in the bio-logistics business.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023Yes----

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
4212 Local trucking without storage

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Chief Executive Officer, Director Se YeonBaek 56 9/3/2024 9/3/2024
Co-Chief Executive Officer, Director Gyeong RyulLee 62 3/13/2023 12/28/2022
Internal Auditor Dae YeongKim 59 12/28/2022 12/28/2022
Director Hyeon WukCho 51 12/28/2022 12/28/2022
Non-Executive Independent Director Jeong GyunChoi 48 9/3/2024 9/3/2024

General Information
Outstanding Shares: 7,283,401 (As of 9/30/2024)
Shareholders: 3,694
Stock Exchange: KDQ
Fax Number: +82 269741734


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, November 22, 2024